An eGFR with cystatin C test estimates kidney filtration using the blood level of cystatin C, either alone or together with creatinine. The combined creatinine-cystatin C equation is especially useful when a creatinine-only estimate may be inaccurate or when a more precise number could change an important decision. Creatinine can be distorted by muscle mass, diet, supplements, or certain medicines, while cystatin C is much less dependent on muscle. Cystatin C has its own non-kidney influences, including steroid use, thyroid dysfunction, inflammation, and adiposity. Because the two markers have different sources of error, combining them often improves accuracy. The result is reported in mL/min/1.73 m² and is interpreted using the same GFR categories as other eGFR values. A cystatin C result should not be read as a separate disease diagnosis; it is a tool for refining how well the kidneys are filtering.
- Combined creatinine-cystatin C eGFR is generally more accurate than eGFR calculated from creatinine or cystatin C alone.
- Cystatin C is especially useful when muscle mass makes creatinine unreliable, including frailty, amputation, severe muscle wasting, or unusually high muscularity.
- The same CKD GFR categories apply: G3a is 45–59, G3b is 30–44, G4 is 15–29, and G5 is below 15 mL/min/1.73 m².
- A one-time low eGFR does not prove chronic kidney disease; CKD requires chronicity for at least three months or other evidence of persistent kidney damage.
- Large disagreement between creatinine and cystatin C estimates matters and should prompt review of body composition, medications, thyroid status, inflammation, and the clinical question.
Table of Contents
- What eGFR With Cystatin C Is
- Creatinine, Cystatin C, and Combined Equations
- When Cystatin C Improves Accuracy
- How to Interpret the Result
- What Discordant eGFR Results Mean
- Preparation and Limitations
- When More Testing Is Needed
What eGFR With Cystatin C Is
Estimated glomerular filtration rate, or eGFR, approximates how much plasma the kidneys filter each minute. Directly measuring GFR is possible, but it requires administration and timed clearance of an external filtration marker, making it too cumbersome for most routine care. eGFR provides a practical estimate from blood tests.
The most common eGFR uses serum creatinine. An eGFR with cystatin C uses the blood concentration of cystatin C, a small protein produced by cells throughout the body. In adults, laboratories may report one or more of the following:
- eGFRcr: estimated from creatinine;
- eGFRcys: estimated from cystatin C;
- eGFRcr-cys: estimated from both creatinine and cystatin C.
The combined value is often the most accurate of the three because it incorporates two markers with different non-GFR influences. Current adult equations are race-free.
The cystatin C blood test itself is reported in mg/L. The eGFR calculation transforms that concentration, along with age and sex where required by the equation, into a filtration estimate that is easier to use clinically.
The result is normalized to a body surface area of 1.73 m². This makes kidney function comparable across adults of different sizes, although clinicians may need a non-indexed value for some drug-dosing decisions or for people at extremes of body size.
Creatinine, Cystatin C, and Combined Equations
Creatinine and cystatin C both rise when kidney filtration falls, but they behave differently outside the kidney. Understanding those differences explains why the combined equation improves accuracy.
Creatinine is produced mainly from muscle. A person with large muscle mass may have a higher creatinine at the same GFR than a frail person. Cooked meat, creatine supplements, intense exercise, and medications that alter tubular creatinine secretion can also change the blood level.
Cystatin C is much less influenced by muscle mass or diet. Its main non-GFR influences include glucocorticoids, thyroid dysfunction, inflammation, adiposity, and some chronic illnesses. These influences are not identical to those affecting creatinine.
| Estimate | Strength | Common limitation |
|---|---|---|
| eGFRcr | Widely available, inexpensive, routinely automated | Muscle mass and creatinine production can distort the result |
| eGFRcys | Less dependent on muscle mass and meat intake | Steroids, thyroid disease, inflammation, and adiposity can influence cystatin C |
| eGFRcr-cys | Usually more accurate and less biased overall | Still an estimate; requires both standardized assays |
A creatinine blood test remains a good first-line marker for most adults. Cystatin C is added when greater accuracy is useful, not because creatinine is inherently poor in every patient.
When Cystatin C Improves Accuracy
The combined estimate is most valuable when creatinine is likely to misrepresent filtration or when the eGFR lies near a decision threshold.
Examples include severe frailty, muscle wasting, paralysis, amputation, neuromuscular disease, very high muscle mass, intensive bodybuilding, and unusual creatine intake. In these situations, creatinine production may differ substantially from the populations used to develop standard equations.
Cystatin C can also help when a creatinine-based eGFR appears inconsistent with the rest of the clinical picture. For example, an older adult with little muscle may have creatinine of 0.8 mg/dL and eGFRcr above 70, yet cystatin C may produce an eGFR around 45. The combined estimate can provide a better basis for staging and medication decisions.
Another important use is near a threshold that changes management. Examples include a drug dose that changes at a certain GFR, eligibility for a procedure, or a transplant evaluation. When a few mL/min/1.73 m² could alter care, reducing estimation error becomes more important.
Current kidney guidance encourages the use of combined creatinine-cystatin C eGFR when cystatin C is available and greater precision is needed. This does not mean every person needs cystatin C at every blood draw. Routine repeat testing is usually based on the clinical question and the stability of kidney function.
How to Interpret the Result
An eGFRcr-cys result is interpreted using standard GFR categories:
| GFR category | eGFR (mL/min/1.73 m²) | Interpretation |
|---|---|---|
| G1 | ≥90 | Normal or high filtration |
| G2 | 60–89 | Mildly decreased |
| G3a | 45–59 | Mild to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | <15 | Kidney failure category |
These categories describe filtration, not the whole kidney diagnosis. For G1 and G2, chronic kidney disease requires another marker of kidney damage, such as persistent albuminuria, urine sediment abnormalities, structural disease, or a kidney transplant history. Chronicity of at least three months is also required unless the kidney disease is otherwise clearly chronic.
The standard eGFR interpretation also applies to cystatin C-based values: trends are often more informative than one measurement. A drop from 80 to 50 over a short period is more concerning than a stable eGFR around 50 over years, although both require context.
Urine albumin-to-creatinine ratio should usually be interpreted alongside eGFR. A person with eGFR 75 and severe albuminuria may have substantial kidney risk, while another person with eGFR 55 and no albuminuria may have a different risk profile.
What Discordant eGFR Results Mean
Discordance means eGFRcr and eGFRcys differ meaningfully. Small differences are expected because both are estimates. A large difference can be clinically important.
If eGFRcys is much lower than eGFRcr, possible explanations include low muscle mass making creatinine falsely reassuring, steroid use or thyroid disease raising cystatin C, inflammation or adiposity influencing cystatin C, or a combination of these factors. Observational research also shows that people whose cystatin C estimate is substantially lower than their creatinine estimate often have higher risks of adverse outcomes.
If eGFRcys is much higher than eGFRcr, creatinine may be elevated by muscle mass, meat intake, creatine supplements, intense exercise, or medicines that interfere with creatinine secretion. Cystatin C may also be unusually low in some settings.
The correct response is not to choose whichever result looks better. Clinicians review the factors that can distort each marker and usually use the combined eGFRcr-cys as the best routine estimate. If the stakes are high and uncertainty remains, measured GFR may be considered.
Discordance can also provide useful prognostic information. Research has linked large differences between the two estimates with mortality, cardiovascular outcomes, and kidney outcomes. The relationship is not a simple direct causal effect of cystatin C; it likely reflects a mixture of kidney function, muscle mass, inflammation, and overall health.
Preparation and Limitations
A cystatin C blood test generally requires no special fasting when ordered alone. A blood sample is taken from a vein, and the laboratory measures cystatin C. If creatinine is being measured at the same time, the lab can calculate eGFRcr-cys when it offers the appropriate equation.
Tell the clinician about glucocorticoid medicines, thyroid disease, major changes in weight or muscle mass, pregnancy, acute infection, inflammatory disease, and supplements. These factors may change how the result is interpreted.
The main limitations of eGFRcr-cys are availability, cost, standardization, and the fact that it remains an estimate. Even the combined equation has a margin of error around measured GFR. Two people with the same reported eGFR can have different true GFR values.
The equations are also less reliable when filtration is changing rapidly. During acute kidney injury, both creatinine and cystatin C lag behind real-time changes to some degree, so a calculated eGFR should not be treated as an exact measurement of current clearance.
For drug dosing, clinicians should follow the dosing method specified for the medicine. Some labels and clinical systems historically use Cockcroft-Gault creatinine clearance, while contemporary guidance increasingly supports validated eGFR approaches. The correct method depends on the drug, patient, and available evidence.
When More Testing Is Needed
A low combined eGFR usually leads to evaluation of chronicity, cause, and kidney damage rather than immediate conclusions from the number alone. Common next steps include repeat kidney blood tests, urine albumin-creatinine ratio, urinalysis, blood pressure review, diabetes testing, and medication assessment.
If kidney function is unexpectedly reduced, clinicians look for reversible causes such as dehydration, infection, urinary obstruction, or a recent medication change. If results remain abnormal for at least three months, the pattern may support chronic kidney disease.
A kidney function blood test panel can place eGFR beside BUN, creatinine, potassium, bicarbonate, and other markers. This is especially important when kidney dysfunction is more advanced because electrolyte and acid-base complications may become clinically significant.
Measured GFR using an external filtration marker may be useful when a highly accurate value is essential and eGFR uncertainty could change a major decision. A creatinine clearance test is another option in selected cases, but 24-hour urine collection errors and tubular creatinine secretion limit its precision.
Seek prompt care if a low eGFR occurs with very low urine output, rapidly increasing swelling, severe shortness of breath, confusion, persistent vomiting, or a dangerous potassium abnormality. The urgency of kidney dysfunction depends on the full clinical picture, not the eGFR number alone.
Practical examples of when the combined eGFR changes decisions
The value of eGFRcr-cys becomes clearest when a more accurate estimate could alter care. Imagine an older adult with marked muscle loss whose creatinine-based eGFR is 68 mL/min/1.73 m². If cystatin C produces an eGFR of 38 and the combined result is 46, the creatinine-only value was probably overly reassuring. That difference could affect medication dosing, CKD counseling, monitoring frequency, and referral decisions.
Now consider a highly muscular adult with creatinine-based eGFR of 52 but no albuminuria and no other sign of kidney disease. If cystatin C-based eGFR is 88 and the combined estimate is 72, the elevated creatinine may partly reflect high creatinine production rather than a true G3a filtration level. The combined result gives a more balanced estimate.
A third example is a patient whose creatinine eGFR is 31 before a treatment that has a dosing boundary at 30. If cystatin C is available, a combined estimate may reduce the chance of making a major decision from a value that is close to the equation’s margin of error. This is exactly the kind of setting in which additional precision is useful.
These examples are illustrative rather than diagnostic cutoffs. The combined equation improves average accuracy, but it still has uncertainty and should not replace clinical judgment.
Accuracy does not mean exactness
No estimating equation reproduces measured GFR perfectly in every person. Accuracy is usually described by how close estimates fall to measured GFR across a population. Even a strong equation can overestimate or underestimate an individual’s true filtration.
This matters when the eGFR is being used for a high-stakes decision. A reported value of 45 mL/min/1.73 m² should not be interpreted as proof that true GFR is exactly 45. Rather, it is the best estimate available from the markers and equation. The uncertainty is usually acceptable for routine CKD staging and monitoring, but measured GFR can be justified when a narrow decision threshold has major consequences.
The combined equation also works best when creatinine and cystatin C assays are standardized. Laboratory methods have improved substantially, but a result from one assay should still be interpreted using the equation and reference system intended for that assay.
How often cystatin C needs to be repeated
There is no universal schedule for repeating cystatin C. In a stable patient, it may be used once to confirm or refine kidney function and then repeated only if the clinical situation changes. In other cases, a clinician may repeat it when creatinine and cystatin C remain discordant, when treatment changes, or when a more precise estimate is again needed.
Routine monitoring can often return to creatinine-based eGFR if the relationship between markers is understood and the patient remains stable. Repeating an expensive or less available marker at every visit does not necessarily add value. The testing strategy should match the decision being made.
How to read the laboratory report
A report may list cystatin C in mg/L and then show one or two derived eGFR values. Look for the label attached to each estimate. eGFRcys means cystatin C was used alone; eGFRcr-cys means both creatinine and cystatin C were used. Do not assume a cystatin C concentration of 1.2 mg/L has the same meaning in every person without the corresponding equation and laboratory context.
If the combined result changes a CKD category, compare it with urine albumin and previous eGFR values before drawing conclusions. A category boundary is useful for standardization, but biological risk changes gradually rather than abruptly at 60, 45, 30, or 15. The combined value should refine the risk picture, not replace it.
For future monitoring, ask whether creatinine alone is sufficient or whether cystatin C should be repeated. Once the relationship between the markers is understood, repeated cystatin C may be reserved for situations in which a more accurate estimate would again change care.
A useful rule is to match test precision to the decision. If a routine annual check shows stable kidney function far from any treatment threshold, creatinine-based eGFR may be enough. If the result will determine a major medication change, procedure, transplant decision, or CKD reclassification and creatinine may be biased, adding cystatin C provides more defensible information.
References
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease 2024 (Guideline)
- Which is the best glomerular filtration marker: Creatinine, cystatin C or both? 2024 (Review)
- Exploring Renal Function Assessment: Creatinine, Cystatin C, and Estimated Glomerular Filtration Rate Focused on the European Kidney Function Consortium Equation 2024 (Review)
- Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR 2022 (Review)
- Discordance between cystatin C-based and creatinine-based estimated glomerular filtration rate and health outcomes in adults: a systematic review and meta-analysis 2025 (Systematic Review)
Disclaimer
eGFR with cystatin C is an estimate of kidney filtration, not a direct measurement and not a stand-alone diagnosis. Results can be affected by non-kidney factors and should be interpreted with creatinine, urine albumin, medical history, medications, and trends over time. A sudden decline or severe symptoms requires prompt clinical assessment.
